Publikationen 2000 - 2002

  1. Creutzig U, Reinhardt D: Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - A European view. Br J Haematol 2002;118:365-377. www.ncbi.nlm.nih.gov/pubmed/12139720
  2. Knaup P, Wiedemann T, Bachert A, Creutzig U, Haux R, Schilling F: Efficiency and safety of chemotherapy plans for children: CATIPO - a nationwide approach. Artificial Intelligence in medicine 2002;24:229-242.
  3. Langebrake C, Reinhardt D, Ritter J: Minimising the long-term adverse effects of childhood leukaemia therapy. Drug Saf 2002;25:1057-1077. www.ncbi.nlm.nih.gov/pubmed/12452732
  4. Puhlmann U, Reinhardt D, Vorwerk H, Ziemann Ch: Association between COX-2 MDR1 expression and MDR1 mediated functional Rhodamine 123 efflux in AML blast. Naunyn-Schmiedeberg's Archives of Pharmakology 2002;365:585.
  5. Reinhardt D, Hempel G, Fleischhack G, Schulz A, Boos J, Creutzig U: [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. Klin Padiatr 2002;214:188-194. www.ncbi.nlm.nih.gov/pubmed/12165900
  6. Reinhardt D, Langebrake C, Creutzig U, Vormoor J, Brune C, Thorwesten M, Ingiliz P, Hrusak O, Dworzak M, Griesinger F: [Minimal residual disease in acute myeloid leukemia in children - standardization and evaluation of immunophenotyping in the AML-BFM-98 study]. Klin Pädiatr 2002;214:179-187. www.ncbi.nlm.nih.gov/pubmed/12165899
  7. Reinhardt D, Thiele C, Creutzig U: [Neuropsychological sequelae in children with AML treated with or without prophylactic CNS-irradiation]. Klin Padiatr 2002;214:22-29. www.ncbi.nlm.nih.gov/pubmed/11823950
  8. Reinhardt D, Zimmermann M, Ritter J, Bender-Götze Ch, Creutzig U: Comparison of Allogeneic Matched Related Stem Cell Transplantation in 1st CR with Chemotherapy alone in Children with High-Risk AML; in Berdel WE, Jürgens H, Büchner Th, Ritter J, Kienast J, Vormoor J, (eds): Transplantation in Hematology and Oncology II. Berlin, Springer Verlag, 2002, pp 210-218.
  9. Reinhardt D, Creutzig U: Isolated myelosarcoma in children--update and review. Leuk Lymphoma 2002;43:565-574. www.ncbi.nlm.nih.gov/pubmed/12002760
  10. Reinhardt D, Hempel G, Fleischhack G, Schulz A, Boos J, Creutzig U: Effektive Rezidivtherapie der akuten myeloischen Leukämie im Kindesalter mit liposomalem Daunorubicin und Cytarabin. Klin Pädiatr 2002;214:188-194.
  11. Selle B, Bar C, Hecker S, Schmidt-Rohr U, Viehmann S, Debatin KM, Reinhardt D: ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL). Leukemia 2002;16:1393-1395. www.ncbi.nlm.nih.gov/pubmed/12094266
  12. Viehmann S, Reinhardt D, Griesinger F, Creutzig U, Harbott J: Monitoring of minimal residual disease (MRD) in children with AML - comparison of two quantitative methods. Monatsschrift Kinderheilkunde 2002;150:553-564.
  13. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Huismans DR, Zimmermann M, Harbott J, Slater RM, Creutzig U, Veerman AJ: Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 2002;100:3352-3360. www.ncbi.nlm.nih.gov/pubmed/12384437
  14. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, Van Zantwijk CH, Huismans DR, de Vries E, Rots MG, Peters GJ, Jansen G, Creutzig U, Veerman AJ: Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002;99:245-251. www.ncbi.nlm.nih.gov/pubmed/11756178
  15. Infektionsprophylaxe bei hämatologisch-onkologischen Patienten in der Pädiatrie: Berichte der Qualitätssicherungsgruppe der GPOH in Zusammenarbeit mit der AG "Infektionen bei Neutropenie" der DGPI: ed Sonderband Klinische Pädiatrie, Stuttgart, Thieme, 2001.
  16. Creutzig U, Berthold F, Boos J, Fleischhack G, Gadner H, Gnekow A, Graubner U, Henze G, Hermann J, Imbach P, Jürgens H, Kabisch H, Körholz D, Niemeyer CM, Reinhardt D, Reiter A, Ritter J, Spaar HJ, Zimmermann M: [Improved treatment results in children with AML: Results of study AML- BFM 93]. Klin Padiatr 2001;213:175-185. www.ncbi.nlm.nih.gov/pubmed/11528551
  17. Creutzig U, Reinhardt D, Zimmermann M, Klingebiel T, Gadner H.: Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia: a matter of controversies. Blood 2001;97:3671-3672.
  18. Creutzig U: Therapie von Tumoren und malignen Systemerkrankungen des Kindes; in Zeller WJ, zur Hausen H, (eds): Onkologie: Grundlagen - Diagnostik - Therapie - Entwicklung. Landsberg, ecomed, 2001, pp 1-24.
  19. Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB, Niemeyer CM, Schwabe D, Selle B, Boos J, Kuhl J, Feldges A: Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia 2001;15:348-354. www.ncbi.nlm.nih.gov/pubmed/11237056
  20. Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, for the AML-BFM Study Group: Risk-Adapted Therapy and Randomization in Children with AML: Preliminary Results of Study AML-BFM 93. Haematol Blood Transf 2001;40:519-524.
  21. Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jürgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H: Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt- Munster 93. J Clin Oncol 2001;19:2705-2713. www.ncbi.nlm.nih.gov/pubmed/11352963
  22. de Haas TGKJ, Zwaan CM, Wondergem MJ, Pieters R, Kaspers GJL, Loonen AH, Rottier MMA, Wünsche R, Creutzig U, Bartl S, Hählen K, Broxterman HJ, Ossenkoppele GJ, Veerman AJP: In-vitro cellular drug resistance in acute non-lymphoblastic leukemia: comparisons between adults and children. Haematol Blood Transf 2001;40:244-250.
  23. Mann G, Reinhardt D, Ritter J, Hermann J, Schmitt K, Gadner H, Creutzig U: Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 2001;80:417-422. www.ncbi.nlm.nih.gov/pubmed/11529468
  24. Rots MG, Pieters R, Jansen G, Kaspers GJ, Van Zantwijk CH, Noordhuis P, Voorn DA, van Wering ER, Creutzig U, Veerman AJ, Peters GJ: A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia. Eur J Cancer 2001;37:492-498. www.ncbi.nlm.nih.gov/pubmed/11267859
  25. Schrappe M, Creutzig U: Akute lymphoblastische- (ALL) und akute myeloische (AML) Leukämie im Kindesalter.In:Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Pädiatrische Onkologie und Hämatologie. Deutsche Krebsgesellschaft e.V., Informationszentrum für Standards in der Onkologie ISTO AWMF online. http://www.uni-duesseldorf.de/WWW/AWMF/ll/ponk-211.htm.; 2001.
  26. Wuchter C, Ratei R, Spahn G, Schoch C, Harbott J, Schnittger S, Haferlach T, Creutzig U, Sperling C, Karawajew L, Ludwig WD: Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica 2001;86:154-161. www.ncbi.nlm.nih.gov/pubmed/11224484
  27. Creutzig U, Körholz D, Niemeyer CM, Kabisch H, Graf N, Reiter A, Scheel-Walter H, Bender-Gotze C, Behnisch W, Hermann J, Mann G, Ritter J, Zimmermann M: Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children. Klin Padiatr 2000;212:163-168. www.ncbi.nlm.nih.gov/pubmed/10994544
  28. Creutzig U, Körholz D, Niemeyer CM, Kabisch H, Graf N, Reiter A, Scheel-Walter HG, Bender-Götze C, Behnisch W, Hermann J, Mann G, Ritter J, Zimmermann M: 3 x14 mg idarubicin during induction. Results of a pilot study in children with AML. Leukemia 2000;14:340-342.
  29. Dübbers A, Würthwein G, Müller HJ, Schulze-Westhoff P, Winkelhorst M, Kurzknabe E, Lanvers C, Pieters R, Kaspers GJ, Creutzig U, Ritter J, Boos J: Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity. Br J Haematol 2000;109:427-429. www.ncbi.nlm.nih.gov/pubmed/0010848836
  30. Reinhardt D, Pekrun A, Lakomek M, Zimmermann M, Ritter J, Creutzig U: Primary myelosarcomas are associated with a high rate of relapse: report on 34 children from the acute myeloid leukaemia-Berlin-Frankfurt- Munster studies. Br J Haematol 2000;110:863-866. www.ncbi.nlm.nih.gov/pubmed/11054069
  31. Wuchter C, Harbott J, Schoch C, Schnittger S, Borkhardt A, Karawajew L, Ratei R, Ruppert V, Haferlach T, Creutzig U, Dorken B, Ludwig WD: Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. Leukemia 2000;14:1232-1238. www.ncbi.nlm.nih.gov/pubmed/10914547
  32. Zwaan CM, Kaspers GJ, Pieters R, Ramakers-Van Woerden NL, den Boer ML, Wunsche R, Rottier MM, Hahlen K, van Wering ER, Janka-Schaub GE, Creutzig U, Veerman AJ: Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 2000;96:2879-2886. www.ncbi.nlm.nih.gov/pubmed/11023525
Suchen
Benutzeranmeldung